Eficacia y seguimiento en el largo plazo de pacientes con psoriasis vulgar moderada a severa en tratamiento con infliximab (Remicade®)

Background: Psoriasis has a moderate or severe course in 25% of patients, requiring systemic therapy that is not always successful. Infliximab is a human-murine monoclonal anti tumor necrosis alpha (TNF-a) antibody. This mediator has a role in the pathogenesis of psoriasis. Aim: To evaluate the use...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Valdés A,María del Pilar, Schroeder H,Francisca, Roizen G,Vicky, Honeyman M,Juan, Sánchez M,Leonardo
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2006
Materias:	Antibodies, monoclonal infliximab psoriasis
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872006000300009
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872006000300009
record_format	dspace
spelling	oai:scielo:S0034-988720060003000092006-05-02Eficacia y seguimiento en el largo plazo de pacientes con psoriasis vulgar moderada a severa en tratamiento con infliximab (Remicade®)Valdés A,María del PilarSchroeder H,FranciscaRoizen G,VickyHoneyman M,JuanSánchez M,Leonardo Antibodies, monoclonal infliximab psoriasis Background: Psoriasis has a moderate or severe course in 25% of patients, requiring systemic therapy that is not always successful. Infliximab is a human-murine monoclonal anti tumor necrosis alpha (TNF-a) antibody. This mediator has a role in the pathogenesis of psoriasis. Aim: To evaluate the use of infliximab in psoriatic patients resistant to conventional therapies. Material and Methods: An open prospective study including eight patients with extensive plaque or erythrodermic psoriasis. They were treated with infliximab 5 mg/kg/dose on weeks 0,2 and 6. Patients were evaluated every 2 weeks for a median lapse of 50.1 weeks. Physical examination, PASI scores (Psoriasis Area Severity Index) and a photographic control, were done in each visit. Results: All the patients responded in the first 10 weeks of follow-up. The mean reduction in PASI score was 86.6%. Six patients received fourth infusion of infliximab at 37.3 weeks, on average. The most common adverse events were pruritus and headache. Conclusions: This group of patients with extensive plaque or erythrodermic psoriasis resistant to conventional therapies, had a good response to infliximabinfo:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.134 n.3 20062006-03-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872006000300009es10.4067/S0034-98872006000300009
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Antibodies, monoclonal infliximab psoriasis
spellingShingle	Antibodies, monoclonal infliximab psoriasis Valdés A,María del Pilar Schroeder H,Francisca Roizen G,Vicky Honeyman M,Juan Sánchez M,Leonardo Eficacia y seguimiento en el largo plazo de pacientes con psoriasis vulgar moderada a severa en tratamiento con infliximab (Remicade®)
description	Background: Psoriasis has a moderate or severe course in 25% of patients, requiring systemic therapy that is not always successful. Infliximab is a human-murine monoclonal anti tumor necrosis alpha (TNF-a) antibody. This mediator has a role in the pathogenesis of psoriasis. Aim: To evaluate the use of infliximab in psoriatic patients resistant to conventional therapies. Material and Methods: An open prospective study including eight patients with extensive plaque or erythrodermic psoriasis. They were treated with infliximab 5 mg/kg/dose on weeks 0,2 and 6. Patients were evaluated every 2 weeks for a median lapse of 50.1 weeks. Physical examination, PASI scores (Psoriasis Area Severity Index) and a photographic control, were done in each visit. Results: All the patients responded in the first 10 weeks of follow-up. The mean reduction in PASI score was 86.6%. Six patients received fourth infusion of infliximab at 37.3 weeks, on average. The most common adverse events were pruritus and headache. Conclusions: This group of patients with extensive plaque or erythrodermic psoriasis resistant to conventional therapies, had a good response to infliximab
author	Valdés A,María del Pilar Schroeder H,Francisca Roizen G,Vicky Honeyman M,Juan Sánchez M,Leonardo
author_facet	Valdés A,María del Pilar Schroeder H,Francisca Roizen G,Vicky Honeyman M,Juan Sánchez M,Leonardo
author_sort	Valdés A,María del Pilar
title	Eficacia y seguimiento en el largo plazo de pacientes con psoriasis vulgar moderada a severa en tratamiento con infliximab (Remicade®)
title_short	Eficacia y seguimiento en el largo plazo de pacientes con psoriasis vulgar moderada a severa en tratamiento con infliximab (Remicade®)
title_full	Eficacia y seguimiento en el largo plazo de pacientes con psoriasis vulgar moderada a severa en tratamiento con infliximab (Remicade®)
title_fullStr	Eficacia y seguimiento en el largo plazo de pacientes con psoriasis vulgar moderada a severa en tratamiento con infliximab (Remicade®)
title_full_unstemmed	Eficacia y seguimiento en el largo plazo de pacientes con psoriasis vulgar moderada a severa en tratamiento con infliximab (Remicade®)
title_sort	eficacia y seguimiento en el largo plazo de pacientes con psoriasis vulgar moderada a severa en tratamiento con infliximab (remicade®)
publisher	Sociedad Médica de Santiago
publishDate	2006
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872006000300009
work_keys_str_mv	AT valdesamariadelpilar eficaciayseguimientoenellargoplazodepacientesconpsoriasisvulgarmoderadaaseveraentratamientoconinfliximabremicade AT schroederhfrancisca eficaciayseguimientoenellargoplazodepacientesconpsoriasisvulgarmoderadaaseveraentratamientoconinfliximabremicade AT roizengvicky eficaciayseguimientoenellargoplazodepacientesconpsoriasisvulgarmoderadaaseveraentratamientoconinfliximabremicade AT honeymanmjuan eficaciayseguimientoenellargoplazodepacientesconpsoriasisvulgarmoderadaaseveraentratamientoconinfliximabremicade AT sanchezmleonardo eficaciayseguimientoenellargoplazodepacientesconpsoriasisvulgarmoderadaaseveraentratamientoconinfliximabremicade
_version_	1718436250858291200

Eficacia y seguimiento en el largo plazo de pacientes con psoriasis vulgar moderada a severa en tratamiento con infliximab (Remicade®)

Ejemplares similares